BlackRock’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

BlackRock’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-776,613	Closed	-$94M	–	5673
2023 Q1	$94M	Sell	776,613 -7,095	-0.9%	-$816K	﹤0.01%	2058
2022 Q4	$90M	Sell	783,708 -226,111	-22%	-$24.9M	﹤0.01%	2062
2022 Q3	$102M	Buy	1,009,819 +10,943	+1%	+$1.16M	﹤0.01%	1953
2022 Q2	$101M	Sell	998,876 -4,848	-0.5%	-$529K	﹤0.01%	1991
2022 Q1	$117M	Sell	1,003,724 -56,166	-5%	-$6.5M	﹤0.01%	2035
2021 Q4	$122M	Buy	+1,059,890	New	+$121M	﹤0.01%	2069
2020 Q4	–	Sell	-944,639	Closed	-$106M	–	5211
2020 Q3	$106M	Buy	944,639 +18,154	+2%	+$2.03M	﹤0.01%	1843
2020 Q2	$97M	Buy	+926,485	New	+$99.2M	﹤0.01%	1857

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

BlackRock's BSX.PRA Position: Q2 2023 in Review

BlackRock sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 776,613 shares — an estimated $94M sold.

BlackRock first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $122M in Q4 2021. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

BlackRock reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
BlackRock sold 776,613 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $94M.
BlackRock first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
BlackRock's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $122M in Q4 2021.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.